VOCABRIA Drug Patent Profile
✉ Email this page to a colleague
When do Vocabria patents expire, and when can generic versions of Vocabria launch?
Vocabria is a drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this drug.
This drug has one hundred and twenty-six patent family members in thirty-three countries.
The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this compound. Additional details are available on the cabotegravir sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Vocabria
Vocabria was eligible for patent challenges on January 21, 2025.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 28, 2026. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VOCABRIA?
- What are the global sales for VOCABRIA?
- What is Average Wholesale Price for VOCABRIA?
Summary for VOCABRIA
International Patents: | 126 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 20 |
Patent Applications: | 4 |
What excipients (inactive ingredients) are in VOCABRIA? | VOCABRIA excipients list |
DailyMed Link: | VOCABRIA at DailyMed |

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VOCABRIA
Generic Entry Date for VOCABRIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for VOCABRIA
US Patents and Regulatory Information for VOCABRIA
VOCABRIA is protected by three US patents and three FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VOCABRIA is ⤷ Try for Free.
This potential generic entry date is based on patent ⤷ Try for Free.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for VOCABRIA
When does loss-of-exclusivity occur for VOCABRIA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Viet Nam
Patent: 404
Patent: Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Estimated Expiration: ⤷ Try for Free
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VOCABRIA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 20081892 | ⤷ Try for Free | |
Hungary | S2100022 | ⤷ Try for Free | |
Denmark | 3372281 | ⤷ Try for Free | |
Norway | 20161315 | Polysyklisk karbamoylpyridonderivat som har integrase inhibitorisk aktivitet | ⤷ Try for Free |
Denmark | 3045206 | ⤷ Try for Free | |
European Patent Office | 3187226 | DÉRIVÉ DE CARBAMOYLPYRIDONE POLYCYCLIQUE DOTÉ D'UNE ACTIVITÉ INHIBITRICE DE L'INTÉGRASE DU VIH (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY) | ⤷ Try for Free |
France | 14C0041 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VOCABRIA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2465580 | PA2021512,C2465580 | Lithuania | ⤷ Try for Free | PRODUCT NAME: KABOTEGRAVIRAS; REGISTRATION NO/DATE: EU/1/20/1481 20201217 |
2465580 | 132021000000098 | Italy | ⤷ Try for Free | PRODUCT NAME: CABOTEGRAVIR(VOCABRIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1481, 20201221 |
1874117 | PA2014021 | Lithuania | ⤷ Try for Free | PRODUCT NAME: DOLUTEGRAVIRUM NATRICUM; REGISTRATION NO/DATE: EU/1/13/892/001, 2014 01 16 EU/1/13/892/002 20140116 |
1874117 | 122014000066 | Germany | ⤷ Try for Free | PRODUCT NAME: DOLUTEGRAVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER SOLVAT DAVON, EINSCHLIESSLICH DOLUTEGRAVIRNATRIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140116 |
2465580 | 301109 | Netherlands | ⤷ Try for Free | PRODUCT NAME: CABOTEGRAVIR; REGISTRATION NO/DATE: EU/1/20/1481 20201217 |
1874117 | C201430032 | Spain | ⤷ Try for Free | PRODUCT NAME: DOLUTEGRAVIR O UNA SAL O SOLVATO DEL MISMO FARMACEUTICAMENTE ACEPTABLE, INCLUIDA LA SAL SODICA DE DOLUTEGRAVIR.; NATIONAL AUTHORISATION NUMBER: EU/1/13/892; DATE OF AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/892; DATE OF FIRST AUTHORISATION IN EEA: 20140116 |
1874117 | 1491036-8 | Sweden | ⤷ Try for Free | PRODUCT NAME: DOLUTEGRAVIR ELLER ETT FARMACEUTISKT ACCEPTABELT SALT ELLER SOLVAT DAERAV, INKLUSIVE DOLUTEGRAVIRNATRIUM; FIRST MARKETING AUTHORIZATION NUMBER SE: EU/1/13/892, 2014-01-21; |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Vocabria (Cabotegravir)
More… ↓